C0333106||Variceal Bleeding
C1623038||Cirrhosis
C0033107||Primary Prophylaxis
C0333106||variceal bleeding
C1623038||cirrhosis
C0086388||clinical care
C2985505||retrospective cohort study
C1623038||cirrhotic
C0019080||bleeding
C0033497||propranolol
C0027302||nadolol
C0020030||Veterans Administration facility
C0333106||variceal bleeding
C0033489||Cox-proportional hazards analyses
C0554834||dose change
C1997754||heart rate response
C0333106||variceal bleeding
C0333106||variceal bleeding
C1282911||upward
C0205104||downward
C0162621||titration
C0019010||hemodynamic response
C0003962||ascites
C3826979||Model for end-stage liver disease
C3826979||Model for end-stage liver disease
C1718072||scores
C0333106||variceal bleeding
C1282911||upward
C0205104||downward
C0162621||titration
C0019010||hemodynamic response
C0019080||bled
C0033107||primary prophylaxis
C0162621||titration
C0162621||titrated
C1283169||monitoring
C1623038||cirrhotic